Driving value with home NIV: Discover how you could save your organization millions
You may already know the clinical benefits of home NIV, but now discover the significant cost savings this new approach could bring to your organization.
Share this story
Emerging evidence has reinforced the use of home-based noninvasive ventilation (NIV) to treat patients with chronic hypercapnic COPD. This new methodology was proven in the recent HOT-HMV study.1 And now, outcomes of a study published in Value in Health make the clinical and financial benefits of combination therapy truly impossible to ignore.2 Collectively, the reports demonstrate that when you center care on patients, the organizational cost savings follow.
Better for patients
Today, nearly 25% of COPD patients will be readmitted following an acute exacerbation.3 This impacts disease morbidity, worsens their quality of life and drives increased costs and penalties for health systems. Recently, NIV usage has increased in hospitals to treat these exacerbations in patients with severe COPD. But, when patients are discharged, they are often armed only with oxygen, medication and an inhaler. De-escalating the level of care upon discharge is thought to be the culprit responsible for many readmissions.
Contributors
Teofilo Lee-Chiong, MD
Pulmonologist and Chief Medical Liaison Philips
We need to reimagine the way we provide care to patients across the entire care continuum and throughout every stage of disease. We’re not relegated to just medication; we’ve got much more in our wheelhouse.”
Teofilo Lee-Chiong, MD Pulmonologist and Chief Medical Liaison Philips
Now, with the addition of home NIV, patients can maintain the level of care they were receiving in the hospital, even after they leave. And, with the findings published in Value in Health, it is clear that home NIV supports long-term benefits for patients, payers and organizations alike.2
This combination therapy has been shown to1:
Reduce the frequency of exacerbations
Reduce
readmissions
Significantly improve
patients’ quality of life
Better for providers
The Philips-sponsored study, “Cost Savings from Reduced Hospitalizations with Use of Home Noninvasive Ventilation for COPD,” examined the financial benefits of implementing an advanced mode of NIV in the home-care setting. The study revealed that this new approach may lead to reduced readmissions and, therefore, long-term cost savings for both hospitals and payers.2
The cost of patient care should never prevent them from getting the care they need. But, in this case, it really is a win-win.”
Teofilo Lee-Chiong, MD Pulmonologist and Chief Medical Liaison Philips
A deeper look at savings
Beneath the surface level gains, see how different treatment approaches impact the bottom line.
Advanced NIV vs no NIV or RAD
Days 0-30
Days 31-60
Days 61-90
Hospital perspective (n=250 patients with severe COPD)
No NIV or RAD
Cost of admission
$424,912
$513,424
$513,424
Reimbursment
$0
$489,109
$489,109
Total admission cost
$424,912
$24,315
$24,315
Advanced NIV
Cost of admission
$21,931
$26,499
$26,499
Reimbursment
$0
$25,244
$25,244
Total admission cost
$21,931
$1,255
$1,255
Admissions savings
$402,981
$23,060
$23,060
Cumulative admissions savings
$402,981
$426,041
$449,101
Make your case
Undoubtedly, the use of HOT-HMV can put your institution on the cutting edge of care delivery and performance. Don’t let the benefits pass you by. Make it your business to justify the need—and the gains. When you’re ready to begin implementing this new approach, we’ll show you how to lead your organization into the future. By championing this new program, you can create unprecedented value that’s felt throughout your institution and the patients you serve.
Register now for exclusive monthly content like this delivered directly to your inbox
Further reading
COPD insider
As COPD continues to plague millions of people, we continue searching for solutions. Each new initiative or program is another step forward in care delivery. As you and your team embark on new, innovative initiatives, rely on COPD insider for the proven strategies that can bring success closer.
References 1. Murphy PB, Rehal S, Arbane G, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA. 2017;317(21):2177-2186. 2. Coughlin S, Peyerl FW, Munson SH, Ravindranath AJ, Lee-Chiong TL. Cost savings from reduced hospitalizations with use of home noninvasive ventilation for COPD. Value Health. 2017;20(3):379-387. 3. Shah T, Press VG, Huisingh-Scheetz M, White SR. COPD readmissions: addressing COPD in the era of value-based health care. Chest. 2016;150(4):916-926.
All content on this site is for informational and educational purposes only and is not a substitute for medical advice of your doctor or other health care professional. Always seek the advice of your physician or other health care provider with any questions you may have about any medical condition. Refer to the Terms of Use for additional information.
